Drug intelligence / Profile preview

Techglim-2

Development stage
Unknown
Lead developer
Cytech Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Techglim-2 is a branded generic formulation of glimepiride, an oral antidiabetic medication belonging to the sulfonylurea class. Developed and marketed by Cytech Pharma, it is indicated for the management of type 2 diabetes mellitus. Glimepiride acts by binding to the sulfonylurea receptor 1 (SUR1) on the surface of pancreatic beta cells, which leads to the closure of ATP-sensitive potassium (K+ATP) channels. This closure causes cell depolarization, opening of voltage-gated calcium channels, and a subsequent influx of calcium, which triggers the release of insulin. It is typically used as an adjunct to diet and exercise to improve glycemic control in patients whose blood sugar is not adequately controlled by lifestyle changes alone.

Brand names
Techglim-2Techglim2Techglim 2
Other names
glimepiride
02

Targets

SUR1 (Sulfonylurea receptor 1)

Beyond the preview

Go deeper on Techglim-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Techglim-2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call